Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 7/20 | 0.38 |
| ▸ | NPY1R | P25929 | 5/20 | 0.38 |
| ▸ | NPY2R | P49146 | 4/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.38 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20795868 | 1.00 | DPP4 (0.42) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL22848364 | 1.00 | DPP4 (0.42) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL28234596 | 1.00 | DPP4 (0.42) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL25448049 | 0.93 | DPP7 (0.41) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL14887421 | 0.93 | DPP7 (0.41) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL16645050 | 0.93 | DPP7 (0.41) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL29359380 | 0.90 | C3AR1 (0.46) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL6047671 | 0.90 | C3AR1 (0.46) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL16862522 | 0.90 | C3AR1 (0.46) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL28819908 | 0.90 | C3AR1 (0.46) | DPP4DPP8DPP9DPP7NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407457-A1 | ANTI-TRAILR2 ANTIBODY-TOXIN-CONJUGATE AND PHARMACEUTICAL USE THEREOF IN ANTI-TUMOR THERAPY | REMEGEN CO., LTD. (CN) | 2020-12-31 | — | — | US | claimed |
| EP-3753579-A1 | ANTI-TRAILR2 ANTIBODY-TOXIN-CONJUGATE AND PHARMACEUTICAL USE THEREOF IN ANTI-TUMOR THERAPY | Yantai Obioadc Biomedical Technology Ltd. (CN) | 2020-12-23 | — | — | EP | claimed |
| CN-110152014-A | Anti- TRAILR2 Antibody-toxin-conjugate and its medicinal usage in antineoplaston | 和元生物技术（上海）股份有限公司 | 2019-08-23 | — | — | CN | claimed |
| CN-108452320-A | Anti- TRAILR2 Antibody-toxins-conjugate and its medicinal usage in antineoplaston | 和元生物技术（上海）股份有限公司 | 2018-08-28 | — | — | CN | claimed |
| CN-110152014-B | anti-TRAILR 2 antibody-toxin-conjugate and its pharmaceutical use in anti-tumor therapy | 烟台市和元艾迪斯生物医药科技有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-20200407457-A1 | ANTI-TRAILR2 ANTIBODY-TOXIN-CONJUGATE AND PHARMACEUTICAL USE THEREOF IN ANTI-TUMOR THERAPY | REMEGEN CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
| EP-3753579-A1 | ANTI-TRAILR2 ANTIBODY-TOXIN-CONJUGATE AND PHARMACEUTICAL USE THEREOF IN ANTI-TUMOR THERAPY | Yantai Obioadc Biomedical Technology Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| CN-110152014-A | Anti- TRAILR2 Antibody-toxin-conjugate and its medicinal usage in antineoplaston | 和元生物技术（上海）股份有限公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-108452320-A | Anti- TRAILR2 Antibody-toxins-conjugate and its medicinal usage in antineoplaston | 和元生物技术（上海）股份有限公司 | 2018-08-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407457-A1 | ANTI-TRAILR2 ANTIBODY-TOXIN-CONJUGATE AND PHARMACEUTICAL USE THEREOF IN ANTI-TUMOR THERAPY | TNFRSF9, TNFRSF1A, TNFSF10 | DPP4 2999/4885DPP8 2734/4885DPP9 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.